WuXi NextCODE Brings the Global Standard Platform for Genomic Big Data to Microsoft Azure
Microsoft customers can now organize, mine and share genome sequence data using the same technology powering the most advanced precision medicine efforts worldwide
-- More hospitals and provider networks can now use WuXi NextCODE tools online
-- Enables web-based clinical interpretation and reporting for rare diseases and cancer
-- Clinical researchers can create and query vast virtual cohorts without moving big data files
-- Optimizes productivity while minimizing data storage and computing hardware costs
SHANGHAI and CAMBRIDGE, Massachusetts and REYKJAVIK, Iceland, June 28, 2016 /PRNewswire/ -- WuXi NextCODE, a global genomic information and precision medicine company, today announced that its comprehensive genomics platform is now available on Microsoft Azure. By bringing its platform to Azure, WuXi NextCODE will enable an even broader community of healthcare institutions and companies to take advantage of its powerful capabilities for applying genome sequence data to deliver and develop better medicine. The system will be demonstrated at the Microsoft booths at the Develop, Innovate, Advance (DIA) conference in Philadelphia June 28-30 and the Festival of Genomics in Boston June 28-29.
Logo - http://photos.prnewswire.com/prnh/20160628/384108LOGO
Logo - http://photos.prnewswire.com/prnh/20150915/266982LOGO
"Launching our genomics platform on Microsoft Azure marks another exciting step in our development as the standard platform on which precision medicine will be built and delivered," said Hannes Smarason, chief operating officer, WuXi NextCODE. "Microsoft Corp. is a leader in delivering powerful cloud technology. We are thrilled to work with Microsoft experts and customers worldwide to use the genome to benefit patients."
Today, WuXi NextCODE is the only platform that makes it possible to use large-scale genomic data in full resolution over an ordinary internet connection. That means that a pediatrician in the Midwest can send the DNA of a rare disease patient to be sequenced and uploaded to the WuXi NextCODE system on the Azure cloud platform; a clinical geneticist in Boston can use WuXi NextCODE's clinical interface to identify the variant causing the illness; and the doctor, the geneticist and the parents can then review the entire process step-by-step in real time. They can see the child's genome sequence in the context of global reference data in full resolution on their desktops a thousand miles apart, without ever having to send big data files back and forth online or on disk.
The same capability enables teams of scientists to link and instantly query tens of thousands of genomes from many institutions to find new links between genes and diseases. Doing this on Azure means every researcher can access and query all of the same data using WuXi NextCODE's renowned discovery interface and scalable computing power. That eliminates the need to replicate and store multiple copies, and allows IT teams to focus on advanced applications with real scientific and medical impact, rather than managing basic infrastructure.
"Applying genomics to medicine is a big data challenge, and WuXi NextCODE is meeting this challenge with a scalable solution on Microsoft Azure," said David Heckerman, distinguished scientist, Microsoft Genomics. "We are pleased to bring the power and reach of the WuXi NextCODE platform to Microsoft Azure as an integral part of our growing genomics ecosystem."
About WuXi NextCODE
WuXi NextCODE is a genomic information company applying sequence data to deliver better health and precision medicine for people around the world. Our uniquely comprehensive open-access capabilities include CLIA- and CAP-certified sequencing; a novel database architecture that mines and manages more genomes than any other; the world's leading genome interpretation and discovery system, available installed or in the cloud; a pioneering internet of DNA that enables users to query and collaborate using massive genomic datasets online with unrivalled resolution and efficiency; the know-how to apply genomics to optimize drug development; and a growing range of tests and scans to improve rare disease diagnosis, targeted cancer treatment, and wellness. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we serve companies and health systems, clinicians and researchers, and people and populations worldwide. WuXi NextCODE is a subsidiary of WuXi AppTec.
Contact:
Edward Farmer
WuXi NextCODE
efarmer@nextcode.com
+1 (781) 775 6206
Share this article